One of the largest clinical trials, global, held with Greek participation, involving lung cancer, was presented last month at the American Oncology Congress.

At the same time, its results were published in the important medical journal The New England Journal of Medicine.

Many Greek centers participated in the clinical trial, under the coordination of the Director of the 4th Oncology Clinic and Henry Dunnan Clinical Study Unit, Ioannis Mountziou, who is the first writer and central researcher.

The innovative immunotherapy

“A new category of drugs Created with the help of biotechnology and focused on clinical research with a significant number of patients on “Henry Dunnan” and other Greek centers, recorded Reduce up to 40% of the relative risk of death by the disease, enhancing the immune system. It is also particularly important that the new treatment appeared to be best tolerated than chemotherapy And to significantly reduce the rates of highly aggravating symptoms of patients, such as shortness of breath, coughing and chest pain, “said a statement from Henry Dunnan Hospital.

The findings are opening up new therapeutic paths to microcellular cancer, which is an aggressive form of lung cancer, which is responsible for 15-20% of new diagnoses in our country and worldwide.

It is noted that the new therapeutic method has already received approvals for wide application.

In particular, the results of the new therapeutic approach led to the fast (breakthrough) approval of the drug used (of the drug class’T-Cell Engagers“) In the US and other countries (Canada, Brazil, United Kingdom, Japan, Australia).

The approval of the drug in Europe and in our country is expected in 2026.